HIV vaccine

It’s been 30 years since the first World AIDS Day was recognized. Jens Van Roey, M.D., shares how a fateful diagnosis coincidentally that same year transformed him from a humble physician into a tireless champion for those afflicted with the disease.

The company has secured a top ranking on the biennial report—which grades companies on their efforts to make medicine more accessible to those in low- and middle-income countries—for the fourth consecutive time.

It isn’t just music superstars who attend the annual event taking place in New York City and South Africa this year. Johnson & Johnson’s Chief Scientific Officer, Dr. Paul Stoffels, is on the lineup, too. He shares his personal story of why he’s so dedicated to global public health—and how the company is working to prevent HIV infections through an investigational vaccine.

In the lead-up to the recent International AIDS Society Conference on HIV Science in the Netherlands, we sat down with Hanneke Schuitemaker, who’s hard at work on the holy grail of HIV research: a preventive treatment.

As the Next Einstein Forum Global Gathering kicks off in Rwanda this week, we look at how Johnson & Johnson is helping nurture scientific progress across the continent.

As the International AIDS Society Conference on HIV Science kicks off, we’re spotlighting researchers who’ve dedicated their life’s work to tackling the epidemic in groundbreaking ways.

It’s been two years in the making, but the results of a pre-clinical study on an investigational therapy regimen are in. Co-author Hanneke Schuitemaker shares what researchers have learned.

To commemorate Giving Tuesday, a Johnson & Johnson employee recounts a moving trip he took to Africa, where he witnessed firsthand how the company and its partners have helped to advance healthcare—and the continent’s trajectory.

The index looks at companies that do the best job of providing access to medications in developing countries. Johnson & Johnson ranked #2—and here’s why.